Rett Syndrome Awareness Month is about more than understanding the condition. It is also an opportunity to recognise the people and families behind every diagnosis and the importance of continuing to advance research. For Neurotech, that means continuing our work to investigate NTI164 across paediatric neurological disorders where there remains a need for new treatment options. Our Phase I/II Rett syndrome study has provided important clinical evidence for NTI164, with statistically significant and clinically meaningful results reported from the trial. As Rett Syndrome Awareness Month comes to a close, we recognise the Rett community and the families, clinicians, researchers and advocates whose participation and commitment make clinical research possible. #RettSyndromeAwarenessMonth #RettSyndrome #RettAwareness #Neurotech #NTI164 #RareDisease #ClinicalResearch #PaediatricNeurology

Investor Presentation: October 2026 15th Annual Australian Microcap Investment Conference, Melbourne View the full $NTI Presentation here: api.investi.com.au/api/annou… #Neurotech #NTI164 #ASX #MicrocapConference #Biotechnology

We’re looking forward to participating in the 15th Annual Australian Microcap Investment Conference, taking place at the Sofitel Melbourne on Collins on 20–21 October 2026. Executive Chairman Mark Davies will present on Tuesday, 20 October at 2:45pm, providing investors with an update on NTI’s progress, including the pivotal Phase 3 Beyond Harmony clinical trial evaluating NTI164 in children with autism spectrum disorder. We look forward to connecting with investors and sharing more about Neurotech’s clinical development program and the pathway towards potential regulatory registration and commercialisation of NTI164. Event: 15th Annual Australian Microcap Investment Conference Date: Tuesday, 20 October 2026 Time: 2:45pm Venue: Sofitel Melbourne on Collins, Melbourne For more information about the conference: microcapconferences.com/even… $NTI #Neurotech #NTI164 #ASX #MicrocapConference #Biotechnology #ClinicalResearch

As we continue to recognise Rett Syndrome Awareness Month, we’re highlighting the clinical research Neurotech has undertaken with NTI164 in Rett syndrome. Our Phase I/II Rett syndrome clinical trial evaluated daily oral treatment with NTI164 in 14 patients with Rett syndrome. At 12 weeks, 93% of patients showed improvement across four core Rett anchors measured by Clinical Global Impression - Improvement, with 36% rated “very much/much improved”. The Rett Syndrome Behavioural Questionnaire also showed a statistically significant improvement compared with baseline. These results form part of Neurotech’s growing body of clinical evidence for NTI164 across paediatric neurological disorders. #RettSyndromeAwarenessMonth #RettSyndrome #Neurotech #NTI164 #ClinicalTrials #ClinicalResearch #RareDisease #Biotechnology

Understanding Rett syndrome starts with understanding what causes it. Rett syndrome is a rare genetic neurodevelopmental disorder most commonly caused by a spontaneous pathogenic variant in the MECP2 gene, which plays an important role in brain development and the regulation of other gene functions. For children and families living with Rett syndrome, the condition can affect communication, movement and many other aspects of everyday life. Neurotech’s work with NTI164 is focused on paediatric neurological disorders associated with neuroinflammation. Our Phase I/II Rett syndrome clinical trial investigated the effects of daily oral treatment with NTI164 over 16 weeks. This Rett Syndrome Awareness Month, we recognise the families, clinicians, researchers and advocates working to improve understanding and advance new treatment options. #RettSyndromeAwarenessMonth #RettSyndrome #KnowRett #Neurotech #NTI164 #RareDisease #PaediatricNeurology $NTI

October is Rett Syndrome Awareness Month which an opportunity to raise awareness and understanding of this rare neurodevelopmental disorder and the children and families living with it. Rett syndrome can affect almost every aspect of an individual’s life, including their ability to speak, walk, eat and breathe, with symptoms often beginning in early childhood. At Neurotech, Rett syndrome is an important part of our clinical development program for NTI164. Our Phase I/II clinical trial evaluated NTI164 in 14 patients with Rett syndrome, contributing to our broader work to develop new treatment options for paediatric neurological disorders. Throughout October, we’ll be sharing more about Rett syndrome, our clinical research and the results observed with NTI164. #RettSyndromeAwarenessMonth #RettSyndrome #RettAwareness #Neurotech #NTI164 #ClinicalResearch #RareDisease $NTI

We’ve dosed the first patient in our pivotal Phase 3 Beyond Harmony clinical study of NTI164 in Autism Spectrum Disorder, marking a significant milestone for Neurotech. All sites have now been initiated for the national multi-centre, randomised, double-blind, placebo-controlled study, designed to evaluate the efficacy, safety and tolerability of NTI164 in children with ASD. Up to 200 patients are planned for enrolment under Beyond Harmony’s adaptive trial design, with six sites across Australia. Beyond Harmony builds on the clinical evidence generated from Neurotech’s earlier HARMONY Phase II/III study, which demonstrated clinically meaningful and statistically significant benefits across multiple validated measures, together with an excellent safety profile. Our focus is on successfully executing Beyond Harmony and progressing NTI164 toward regulatory registration as a new treatment option for children with ASD. Read the full $NTI #ASX Announcement here: api.investi.com.au/api/annou… #Neurotech #NTI164 #BeyondHarmony #Autism #ASD #Phase3 #ClinicalStudy #ClinicalDevelopment

Mark Davies, Executive Chairman of Neurotech International Ltd, presented to investors at the @NWRcomms investor event last week. Mark provided an update on Neurotech’s recent progress, the continued development of NTI164 and the Company’s clinical and commercialisation strategy. Thank you to everyone who joined us and took the opportunity to hear more about $NTI and our work in paediatric neurological disorders. #Neurotech #NTI164 #Biotechnology #ClinicalResearch #NeurodevelopmentalDisorders #ASX

“It’s changed every aspect of life.” In this clip from A Current Affair, Libby Harper and her son Tate share their experience following Tate’s participation in Neurotech’s NTI164 clinical trial. Tate talks about being able to stay at school for the whole day, while Libby reflects on the everyday changes that have made such a difference to their family; from getting through the morning to completing four days of school in a row. For Libby, the most significant part has been seeing that progress continue. Thank you to Libby and Tate for sharing their story and helping bring greater awareness to the experiences of families living with autism spectrum disorder. Watch the full $NTI episode here: youtu.be/24FMj7WOXJk?si=rVhB… #Neurotech #NTI #NTI164 #Autism #ASD #ClinicalResearch #NeurodevelopmentalDisorders #PaediatricHealth #Biotechnology @Ninecomau @ACurrentAffair9

We've appointed Mark Davies as Executive Chairman. As Executive Chairman, Mr Davies will assume a more active role in the strategic and operational leadership of Neurotech, including corporate strategy, capital markets and funding initiatives, partnering and licensing activities, investor engagement, governance, and strategic oversight of the Company's clinical and regulatory programs. The appointment reflects Neurotech's progression into its next stage of development, with an increased focus on the Phase III program, funding strategy and potential partnering and licensing opportunities. Read the full $NTI #ASX Announcement here: api.investi.com.au/api/annou…